Health status at long‐term follow‐up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: A Scandinavian sarcoma group study
Authors:
- 2 April 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (1) , 84-89
Abstract
Background: The purpose of this study was to evaluate late effects and symptom complaints in long‐term survivors (>5 years) of Extremity Bone Sarcoma (EBS survivors). The results were compared with findings in age‐ and gender‐matched individuals from the general population (NORMs).Patients and Methods: Among 155 EBS survivors approached, 133 (86%) were included, and 110 of them (83%) attended an outpatient examination. Health status was evaluated by a mailed questionnaire concerning demographic and current health issues, and physical examinations at the outpatient clinic. Age‐ and gender‐adjusted normative controls were drawn from participants of the Health Study of Nord‐Trøndelag County (HUNT 2).Results: Median age at follow‐up was 29 (15–57) years. Median follow‐up was 12 (6–22) years. Of EBS survivors 42% had ≥1 somatic disease, 33% had ototoxicity and 13% had reduced renal function. EBS survivors were more likely to have heart disease (odds ratio [OR], 7.9; 95% confidence interval [95% CI], 2.5–25.3; P = 0.001), hypertension (OR, 3.4; 95% CI, 1.1–10.1; P = 0.03) and thyroid disease (OR, 3.0; 95% CI, 1.1–8.3; P = 0.04) compared to NORMs. EBS survivors reported more diarrhoea (29% vs. 19%, P = 0.02), palpitations (23% vs. 13%, P = 0.01) and shortness of breath (11% vs. 5%, P = 0.01) than NORMs.Conclusions: EBS survivors have poorer health status compared to age‐ and gender‐matched controls. Long‐term follow‐up of these patients is therefore mandatory. Pediatr Blood Cancer 2009;53:84–89.Keywords
This publication has 49 references indexed in Scilit:
- Medical Assessment of Adverse Health Outcomes in Long-term Survivors of Childhood CancerJAMA, 2007
- Young survivors of malignant bone tumours in the extremities: a comparative study of quality of life, fatigue and mental distressSupportive Care in Cancer, 2007
- Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer SurvivorsJournal of Clinical Oncology, 2007
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance systemPediatric Blood & Cancer, 2006
- Scandinavian Sarcoma Group Osteosarcoma Study SSG VIIIEuropean Journal of Cancer, 2003
- SF-36 Health Survey UpdateSpine, 2000
- Development of a fatigue scaleJournal of Psychosomatic Research, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administrationEuropean Journal of Cancer and Clinical Oncology, 1983